Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
107.62
-2.08 (-1.90%)
At close: Mar 28, 2025, 4:00 PM
107.00
-0.62 (-0.58%)
After-hours: Mar 28, 2025, 5:30 PM EDT
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Ligand Pharmaceuticals stock have an average target of 145, with a low estimate of 135 and a high estimate of 160. The average target predicts an increase of 34.73% from the current stock price of 107.62.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 23, 2024.
Analyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Benchmark | Benchmark | Strong Buy Reiterates $135 | Strong Buy | Reiterates | $135 | +25.44% | Dec 23, 2024 |
| Barclays | Barclays | Buy Maintains $150 → $160 | Buy | Maintains | $150 → $160 | +48.67% | Dec 16, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $141 → $143 | Buy | Maintains | $141 → $143 | +32.87% | Dec 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Dec 11, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $130 → $140 | Buy | Maintains | $130 → $140 | +30.09% | Nov 12, 2024 |
Financial Forecast
Revenue This Year
195.38M
from 167.13M
Increased by 16.90%
Revenue Next Year
231.08M
from 195.38M
Increased by 18.27%
EPS This Year
6.27
from -0.22
EPS Next Year
7.00
from 6.27
Increased by 11.54%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 206.4M | 255.3M | 321.2M | ||
| Avg | 195.4M | 231.1M | 268.7M | ||
| Low | 179.3M | 204.3M | 234.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 23.5% | 30.6% | 39.0% | ||
| Avg | 16.9% | 18.3% | 16.3% | ||
| Low | 7.3% | 4.6% | 1.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.83 | 7.93 | 10.14 | ||
| Avg | 6.27 | 7.00 | 9.85 | ||
| Low | 5.74 | 5.71 | 9.47 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 26.4% | 45.0% | ||
| Avg | - | 11.5% | 40.8% | ||
| Low | - | -8.9% | 35.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.